JP2018512168A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018512168A5 JP2018512168A5 JP2017564951A JP2017564951A JP2018512168A5 JP 2018512168 A5 JP2018512168 A5 JP 2018512168A5 JP 2017564951 A JP2017564951 A JP 2017564951A JP 2017564951 A JP2017564951 A JP 2017564951A JP 2018512168 A5 JP2018512168 A5 JP 2018512168A5
- Authority
- JP
- Japan
- Prior art keywords
- fusion protein
- protein according
- claudin
- amino acid
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15157911.7 | 2015-03-06 | ||
| EP15157911.7A EP3064507A1 (en) | 2015-03-06 | 2015-03-06 | Fusion proteins comprising a binding protein and an interleukin-15 polypeptide having a reduced affinity for IL15ra and therapeutic uses thereof |
| PCT/EP2016/054729 WO2016142314A1 (en) | 2015-03-06 | 2016-03-07 | FUSION PROTEINS COMPRISING A BINDING PROTEIN AND AN INTERLEUKIN-15 POLYPEPTIDE HAVING A REDUCED AFFINITY FOR IL15Ra AND THERAPEUTIC USES THEREOF |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018512168A JP2018512168A (ja) | 2018-05-17 |
| JP2018512168A5 true JP2018512168A5 (enExample) | 2019-04-11 |
| JP6757338B2 JP6757338B2 (ja) | 2020-09-16 |
Family
ID=52629425
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017564951A Expired - Fee Related JP6757338B2 (ja) | 2015-03-06 | 2016-03-07 | 結合タンパク質と、ＩＬ１５Ｒαに対する低下した親和性を有するインターロイキン１５ポリペプチドとを含む融合タンパク質、及び、その治療的使用 |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US10906952B2 (enExample) |
| EP (2) | EP3064507A1 (enExample) |
| JP (1) | JP6757338B2 (enExample) |
| CN (1) | CN107636015A (enExample) |
| BR (1) | BR112017018975A2 (enExample) |
| CA (1) | CA2978808A1 (enExample) |
| CY (1) | CY1122494T1 (enExample) |
| DK (1) | DK3265478T3 (enExample) |
| ES (1) | ES2763598T3 (enExample) |
| HR (1) | HRP20192190T1 (enExample) |
| HU (1) | HUE047818T2 (enExample) |
| PL (1) | PL3265478T3 (enExample) |
| PT (1) | PT3265478T (enExample) |
| RS (1) | RS59658B1 (enExample) |
| SI (1) | SI3265478T1 (enExample) |
| WO (1) | WO2016142314A1 (enExample) |
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6400470B2 (ja) | 2011-05-16 | 2018-10-03 | ジェネロン（シャンハイ）コーポレイション リミテッド | 多重特異性Ｆａｂ融合タンパク質および使用法 |
| EP3805371A1 (en) | 2014-05-15 | 2021-04-14 | National University of Singapore | Modified natural killer cells and uses thereof |
| EP3064507A1 (en) * | 2015-03-06 | 2016-09-07 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Fusion proteins comprising a binding protein and an interleukin-15 polypeptide having a reduced affinity for IL15ra and therapeutic uses thereof |
| CN112574316A (zh) | 2015-07-02 | 2021-03-30 | 博际生物医药科技(杭州)有限公司 | 用于肿瘤靶向治疗的白细胞介素-15融合蛋白 |
| WO2017157305A1 (en) | 2016-03-15 | 2017-09-21 | Generon (Shanghai) Corporation Ltd. | Multispecific fab fusion proteins and use thereof |
| CN109715196A (zh) | 2016-06-13 | 2019-05-03 | 转矩医疗股份有限公司 | 用于促进免疫细胞功能的组合物和方法 |
| MX2019004327A (es) | 2016-10-14 | 2019-10-14 | Xencor Inc | Proteinas de fusion heterodimericas biespecificas que contienen proteinas de fusion fc il-15/il-15ra y fragmentos de anticuerpo pd-1. |
| US11629340B2 (en) | 2017-03-03 | 2023-04-18 | Obsidian Therapeutics, Inc. | DHFR tunable protein regulation |
| CN117363636A (zh) | 2017-03-27 | 2024-01-09 | 新加坡国立大学 | 一种编码嵌合受体的多核苷酸 |
| MX2019011570A (es) | 2017-03-27 | 2019-11-18 | Nat Univ Singapore | Lineas celulares estimuladoras para expansion y activacion ex vivo de celulas asesinas naturales. |
| KR102461885B1 (ko) | 2017-04-03 | 2022-11-03 | 에프. 호프만-라 로슈 아게 | 항-pd-1 항체와 돌연변이 il-2 또는 il-15의 면역접합체 |
| AU2018291497A1 (en) | 2017-06-30 | 2020-01-16 | Xencor, Inc. | Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15Ra and antigen binding domains |
| WO2019032628A1 (en) | 2017-08-07 | 2019-02-14 | The Regents Of The University Of California | GENERATING PLATFORM FOR SAFE CELLULAR THERAPEUTIC AGENTS |
| CA3074826A1 (en) | 2017-09-05 | 2019-03-14 | Torque Therapeutics, Inc. | Therapeutic protein compositions and methods of making and using the same |
| AU2018338786A1 (en) * | 2017-09-29 | 2020-04-16 | Nantcell, Inc. | Antigenic proteins and methods therefor |
| JP7360174B2 (ja) | 2018-02-09 | 2023-10-12 | ナショナル ユニヴァーシティー オブ シンガポール | ナチュラルキラー細胞免疫療法における活性化キメラ受容体及びその使用 |
| AU2019224159B2 (en) * | 2018-02-26 | 2025-05-29 | Sanofi | IL-15 conjugates and uses thereof |
| MX387358B (es) * | 2018-02-28 | 2025-03-18 | Pfizer | Variantes de il-15 y usos de las mismas |
| US12441787B2 (en) | 2018-04-02 | 2025-10-14 | National University Of Singapore | Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells |
| CA3097625A1 (en) | 2018-04-18 | 2019-10-24 | Xencor, Inc. | Il-15/il-15ra heterodimeric fc fusion proteins and uses thereof |
| CA3097593A1 (en) | 2018-04-18 | 2019-10-24 | Xencor, Inc. | Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof |
| WO2019204646A1 (en) | 2018-04-18 | 2019-10-24 | Xencor, Inc. | Lag-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and lag-3 antigen binding domains |
| KR20210003814A (ko) | 2018-04-18 | 2021-01-12 | 젠코어 인코포레이티드 | IL-15/IL-15Rα Fc-융합 단백질 및 TIM-3 항원 결합 도메인을 함유하는 TIM-3 표적화 이종이량체 융합 단백질 |
| WO2019246142A1 (en) * | 2018-06-18 | 2019-12-26 | Haiming Chen | Soluble bispecific fusion proteins for cancer immunotherapy |
| CA3102036A1 (en) * | 2018-06-18 | 2019-12-26 | Anwita Biosciences, Inc. | Cytokine fusion proteins and uses thereof |
| WO2020044239A1 (en) | 2018-08-29 | 2020-03-05 | National University Of Singapore | A method to specifically stimulate survival and expansion of genetically-modified immune cells |
| EP3847196A4 (en) | 2018-09-07 | 2023-01-04 | ITabMed (HK) Limited | BISPECIFIC ANTIGEN BINDING PROTEINS AND USES THEREOF |
| CN109207430A (zh) * | 2018-09-25 | 2019-01-15 | 华东师范大学 | 一种嵌合抗原受体nk细胞及其制备方法和应用 |
| CN113286812B (zh) | 2018-09-27 | 2025-05-30 | 西里欧发展公司 | 掩蔽型细胞因子多肽 |
| JP6935383B2 (ja) * | 2018-09-27 | 2021-09-15 | 公益財団法人実験動物中央研究所 | 免疫不全マウス |
| CA3116188A1 (en) | 2018-10-12 | 2020-04-16 | Xencor, Inc. | Pd-1 targeted il-15/il-15ralpha fc fusion proteins and uses in combination therapies thereof |
| CN113226340A (zh) | 2018-11-26 | 2021-08-06 | 恩卡尔塔公司 | 同时扩增多种免疫细胞类型的方法、相关组合物及其在癌症免疫疗法中的用途 |
| US11618776B2 (en) | 2018-12-20 | 2023-04-04 | Xencor, Inc. | Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15RA and NKG2D antigen binding domains |
| WO2020132810A1 (en) | 2018-12-24 | 2020-07-02 | Generon (Shanghai) Corporation Ltd. | Multispecific antigen binding proteins capable of binding cd19 and cd3, and use thereof |
| KR20210137085A (ko) | 2019-03-05 | 2021-11-17 | 엔카르타, 인크. | Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도 |
| SG11202111409YA (en) | 2019-05-20 | 2021-12-30 | Cytune Pharma | IL-2/IL-15Rßy AGONIST DOSING REGIMENS FOR TREATING CANCER OR INFECTIOUS DISEASES |
| AU2020315213A1 (en) * | 2019-07-17 | 2022-02-03 | National University Of Singapore | Functional binders synthesized and secreted by immune cells |
| TW202128757A (zh) | 2019-10-11 | 2021-08-01 | 美商建南德克公司 | 具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白 |
| CN111690068B (zh) * | 2019-11-13 | 2022-04-19 | 中国科学技术大学 | 一种IL-15/SuIL-15Rα-dFc-γ4复合体蛋白及其构造方法、应用 |
| EP3822288A1 (en) | 2019-11-18 | 2021-05-19 | Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts | Antibodies targeting, and other modulators of, the cd276 antigen, and uses thereof |
| CN114761433B (zh) * | 2019-12-11 | 2025-07-29 | 上海复宏汉霖生物技术股份有限公司 | 一种抗Claudin18.2单克隆抗体、其制备方法及用途 |
| CA3193073A1 (en) * | 2020-09-17 | 2022-03-24 | Liping SONG | Bispecific recombinant protein and use thereof |
| KR20230096047A (ko) | 2020-10-26 | 2023-06-29 | 싸이튠 파마 | 비흑색종 피부암 치료용 IL-2/IL-15Rβγ 작용제 |
| WO2022090203A1 (en) | 2020-10-26 | 2022-05-05 | Cytune Pharma | IL-2/IL-15Rβү AGONIST FOR TREATING SQUAMOUS CELL CARCINOMA |
| EP4251187A4 (en) | 2020-11-25 | 2025-09-10 | Xilio Dev Inc | TUMOR-SPECIFIC CLASSIBLE LINKERS |
| CN116635407A (zh) * | 2020-12-23 | 2023-08-22 | 瑞泽恩制药公司 | 编码锚修饰的抗体的核酸以及其用途 |
| JP2024526080A (ja) | 2021-06-23 | 2024-07-17 | サイチューン ファーマ | インターロイキン１５多様体 |
| WO2023280287A1 (en) * | 2021-07-09 | 2023-01-12 | Nanjing Legend Biotech Co., Ltd. | Interleukin-15 variants and uses thereof |
| US20240350589A1 (en) | 2021-08-13 | 2024-10-24 | Cytune Pharma | Il-2/il-15rbetagamma agonist combination with antibody-drug conjugates for treating cancer |
| CN113956346B (zh) * | 2021-10-26 | 2024-03-01 | 西安龙腾景云生物科技有限公司 | 一种重组白介素-15变体 |
| CN115141283A (zh) * | 2022-03-10 | 2022-10-04 | 厦门柏慈生物科技有限公司 | 一种融合蛋白、制备方法及其应用 |
| CN119997975A (zh) * | 2022-10-19 | 2025-05-13 | 安斯泰来制药株式会社 | 抗cldn4-抗cd137双特异性抗体通过与pd-1信号抑制剂的组合在癌症治疗中的应用 |
| CN120693344A (zh) * | 2023-02-14 | 2025-09-23 | 德国癌症研究公共权益基金会 | 具有改善的特性的il-15融合蛋白 |
| WO2024215987A1 (en) | 2023-04-14 | 2024-10-17 | Sotio Biotech Inc. | IMMUNE CELLS FOR TREATING CANCER IN COMBINATION WITH IL-15/IL-15Rα CONJUGATES |
| EP4694916A1 (en) | 2023-04-14 | 2026-02-18 | SOTIO Biotech Inc. | Engineered immune cells for treating cancer in combination with il-2/il-15 receptor ?? agonists |
| WO2025147512A1 (en) * | 2024-01-02 | 2025-07-10 | Eli Lilly And Company | Immunogenicity assessment platform for biotherapeutic proteins |
| WO2025151752A1 (en) | 2024-01-10 | 2025-07-17 | Xilio Development, Inc. | Masked il-2 cytokines and methods of use thereof |
| WO2025222129A2 (en) * | 2024-04-19 | 2025-10-23 | Mozart Therapeutics, Inc. | Engineered cytokines and targeted cytokine delivery |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6107090A (en) | 1996-05-06 | 2000-08-22 | Cornell Research Foundation, Inc. | Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| CA2326389C (en) | 1998-04-21 | 2007-01-23 | Micromet Gesellschaft Fur Biomedizinische Forschung Mbh | Novel cd19xcd3 specific polypeptides and uses thereof |
| DE19926068C1 (de) | 1999-06-08 | 2001-01-11 | Arne Skerra | Muteine des Bilin-Bindungsproteins |
| US7118915B2 (en) | 2001-09-27 | 2006-10-10 | Pieris Proteolab Ag | Muteins of apolipoprotein D |
| WO2003029462A1 (en) | 2001-09-27 | 2003-04-10 | Pieris Proteolab Ag | Muteins of human neutrophil gelatinase-associated lipocalin and related proteins |
| US20040132101A1 (en) * | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| AU2004242846A1 (en) | 2003-05-31 | 2004-12-09 | Micromet Ag | Pharmaceutical compositions comprising bispecific anti-CD3, anti-CD19 antibody constructs for the treatment of B-cell related disorders |
| WO2005019255A1 (en) | 2003-08-25 | 2005-03-03 | Pieris Proteolab Ag | Muteins of tear lipocalin |
| US7691970B2 (en) | 2003-08-25 | 2010-04-06 | Pieris Ag | Muteins of a bilin-binding protein with affinity for a given target |
| ES2367027T3 (es) * | 2004-02-27 | 2011-10-27 | Inserm (Institut National De La Santé Et De La Recherche Medicale) | Sitio de unión de la il-15 para il-15ralfa y mutantes específicos de il-15 que tienen actividad agonista/antagonista. |
| US7892827B2 (en) | 2004-11-26 | 2011-02-22 | Pieris Ag | Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4) |
| ZA200704908B (en) * | 2004-12-13 | 2008-10-29 | Cytos Biotechnology Ag | IL-15 Antigen Arrays and uses thereof |
| DE602007009995D1 (de) | 2006-08-01 | 2010-12-02 | Pieris Ag | Muteine von tearlipocalin und verfahren zu deren gewinnung |
| EP2388266B1 (en) * | 2007-05-11 | 2014-04-23 | Altor BioScience Corporation | Fusion molecules and IL-15 variants |
| CN102511007B (zh) | 2009-10-02 | 2015-04-15 | 罗切格利卡特公司 | 抗体中的a-岩藻糖基化检测 |
| BR112012013662B1 (pt) | 2009-12-07 | 2022-08-02 | Pieris Pharmaceuticals Gmbh | Muteínas de lipocalina associada à gelatinase de neutrófilo humano (lcn2, hngal), seu uso e seus métodos de geração e produção, molécula de ácido nucleico, célula hospedeira, composição farmacêutica e kit de diagnóstico ou analítico |
| JP6251570B2 (ja) | 2010-09-21 | 2017-12-20 | アルター・バイオサイエンス・コーポレーション | 多量体ｉｌ−１５可溶性融合分子並びにその製造及び使用方法 |
| CN104203981A (zh) | 2011-12-19 | 2014-12-10 | 合成免疫股份有限公司 | 双特异性抗体分子 |
| EP3013356B1 (en) | 2013-06-27 | 2018-10-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Interleukin 15 (il-15) antagonists and uses thereof for the treatment of autoimmune diseases and inflammatory diseases |
| EP3064507A1 (en) * | 2015-03-06 | 2016-09-07 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Fusion proteins comprising a binding protein and an interleukin-15 polypeptide having a reduced affinity for IL15ra and therapeutic uses thereof |
| MX387358B (es) | 2018-02-28 | 2025-03-18 | Pfizer | Variantes de il-15 y usos de las mismas |
-
2015
- 2015-03-06 EP EP15157911.7A patent/EP3064507A1/en not_active Withdrawn
-
2016
- 2016-03-07 US US15/556,282 patent/US10906952B2/en not_active Expired - Fee Related
- 2016-03-07 RS RS20191593A patent/RS59658B1/sr unknown
- 2016-03-07 EP EP16708154.6A patent/EP3265478B1/en not_active Revoked
- 2016-03-07 PL PL16708154T patent/PL3265478T3/pl unknown
- 2016-03-07 SI SI201630550T patent/SI3265478T1/sl unknown
- 2016-03-07 CA CA2978808A patent/CA2978808A1/en active Pending
- 2016-03-07 BR BR112017018975-5A patent/BR112017018975A2/pt not_active Application Discontinuation
- 2016-03-07 JP JP2017564951A patent/JP6757338B2/ja not_active Expired - Fee Related
- 2016-03-07 DK DK16708154.6T patent/DK3265478T3/da active
- 2016-03-07 PT PT167081546T patent/PT3265478T/pt unknown
- 2016-03-07 HU HUE16708154A patent/HUE047818T2/hu unknown
- 2016-03-07 ES ES16708154T patent/ES2763598T3/es active Active
- 2016-03-07 HR HRP20192190TT patent/HRP20192190T1/hr unknown
- 2016-03-07 CN CN201680025275.8A patent/CN107636015A/zh active Pending
- 2016-03-07 WO PCT/EP2016/054729 patent/WO2016142314A1/en not_active Ceased
-
2019
- 2019-12-11 CY CY20191101303T patent/CY1122494T1/el unknown
-
2020
- 2020-12-22 US US17/130,975 patent/US20210163564A1/en not_active Abandoned
-
2021
- 2021-12-30 US US17/565,942 patent/US20220324931A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20192190T1 (hr) | Fuzijski proteini koji sadrže vežući protein i polipeptid interleukin-15 sa smanjenim afinitetom za il15ra i njihova upotreba u terapiji | |
| JP2015502373A5 (enExample) | ||
| JP2014088414A5 (enExample) | ||
| PH12020551391A1 (en) | Antibodies against signal-regulatory protein alpha and methods of use | |
| AR120585A1 (es) | Proteínas de unión a antígenos que se unen específicamente a mage-a | |
| JP2021054859A5 (enExample) | ||
| JP2016516789A5 (enExample) | ||
| JP2017504577A5 (enExample) | ||
| JP2018523485A5 (enExample) | ||
| HRP20170658T1 (hr) | Molekula bispecifičnog protutijela | |
| JP2014518615A5 (enExample) | ||
| JP2014505463A5 (enExample) | ||
| JP2019516665A5 (enExample) | ||
| JP2019519227A5 (enExample) | ||
| RU2018109350A (ru) | Химерный цитокиновый рецептор | |
| JP2020503891A5 (enExample) | ||
| PH12018502158B1 (en) | T cell receptors | |
| HRP20211788T1 (hr) | Postupak i pripravci za poboljšanje anti-tumorskog efektorskog funkcioniranja t stanica | |
| AR084210A1 (es) | PROTEINAS DE UNION AL TNF-a | |
| JP2012526530A5 (enExample) | ||
| RU2016124179A (ru) | СКОНСТРУИРОВАННЫЕ ВЫСОКОАФФИННЫЕ T-клеточные рецепторы человека | |
| WO2012135854A3 (en) | T cell receptor-like antibodies specific for a wt1 peptide presented by hla-a2 | |
| JP2014221064A5 (enExample) | ||
| JP2010006705A5 (enExample) | ||
| MX2022004906A (es) | Moleculas de union especifica. |